Publications by authors named "Michael Aboud"

Claim this Profile
E
Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Michael Aboud

HIV Med· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".
Mark Underwood, Joe Horton, Keith Nangle, Judy Hopking, Kimberly Smith, Michael Aboud

Antimicrob Agents Chemother· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Michael Aboud

Clin Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Pedro Cahn, Juan Sierra Madero, José R Arribas, Andrea Antinori, Roberto Ortiz, Michael Aboud

AIDS· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Mark Underwood, Joe Horton, Keith Nangle, Judy Hopking, Kimberly Smith, Michael Aboud

Antimicrob Agents Chemother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of indocyanine green fluorescence lymphangiography and magnetic resonance lymphangiography to investigate lymphedema of the extremities.
Francesco Gentili, Francesco Giuseppe Mazzei, Ilaria Monteleone, Guido Gabriele, Andrea Nigri, Michael Gasser Aboud

Ann Ital Chir· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Amy G Cutrell, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Romina Quercia, Michael Aboud

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral therapy and liver disorders in the OPERA cohort.
Michael Wohlfeiler, Karam Mounzer, Laurence Brunet, Jennifer Fusco, Vani Vannappagari, Michael Aboud

Ther Adv Drug Saf· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Jean van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Michael Aboud

Clin Infect Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Vani Vannappagari, Leigh Ragone, Cassidy Henegar, Jean van Wyk, Dannae Brown, Michael Aboud

Antivir Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Jennifer Fusco, Cassidy Henegar, Evelyn Byrd Quinlivan, Vani Vannappagari, Michael Aboud

Curr HIV Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, Jihad Slim, Vicenç Falcó, Michael Aboud

J Acquir Immune Defic Syndr· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Pedro Cahn, Juan Sierra Madero, José R Arribas, Andrea Antinori, Roberto Ortiz, Michael Aboud

J Acquir Immune Defic Syndr· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Kelly E Dooley, Richard Kaplan, Noluthando Mwelase, Beatriz Grinsztejn, Eduardo Ticona, Michael Aboud

Clin Infect Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.
Melissa Crawford, Jean van Wyk, Michael Aboud, Vani Vannappagari, Beth Romach

J Acquir Immune Defic Syndr· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA Observational Database.
Gerald Pierone, Cassidy Henegar, Jennifer Fusco, Vani Vannappagari, Michael Aboud

J Int AIDS Soc· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Michael Aboud, Chloe Orkin, Daniel Podzamczer, Johannes R Bogner, David Baker

Lancet HIV· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.
Jason Gillman, Patrick Janulis, Roy Gulick, Carole L Wallis, Baiba Berzins, Michael Aboud

J Antimicrob Chemother· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A Hidalgo

Lancet Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Michael Aboud

Lancet· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.
Ricky Hsu, Jennifer Fusco, Cassidy Henegar, Karam Mounzer, Michael Wohlfeiler, Michael Aboud

Ther Adv Drug Saf· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Michael Aboud

Lancet· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
Grace A McComsey, Sergio Lupo, David Parks, Mónica Coronado Poggio, Joseph De Wet, Michael Aboud

AIDS· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Michael Aboud

Lancet HIV· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Michael Aboud

Antivir Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis